/
ERNA
$4.30-$0.12 (-2.71%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$5.2M
1M shares
52-week range
$3.18 – $71.50
2% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Change$-1840.70
Ernexa Therapeutics Inc. Common Stock
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
www.ernexatx.com- Employees
- 5
- IPO / List date
- Mar 26, 2021
- HQ
- CAMBRIDGE, MA
Held by traders on TradeandTell
No one on the platform currently holds ERNA.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ERNA as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-05-04 | 1-for-25reverse |
| 2025-06-12 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded ERNA yet.
